We next investigated the impact of eGlx damage in diabetes and determined whether treatment with the heparanase inhibitor OVZ/HS-1638 could prevent systemic eGlx damage and the associated permeability increases in a T2D mouse model using db/db mice (Fig. 4a). Here, HPSE is linked to diabetes mellitus.